Shimon Eckhouse, the co-founder and Chairman of Syneron Candela. I also believe that this transaction represents a positive outcome for our shareholders," said Dr. We are confident that Apax will add significant value and expertise as Syneron Candela executes on its growth strategy while delivering innovative technologies to our customers and patients. These exceptional assets are a result of the many years of hard work of our skillful and dedicated employees all over the world. "This acquisition is a strong recognition of Syneron Candela's leadership in the aesthetic medical device market, its leading world-class technology and unique global footprint. The per share acquisition price represents a 15% premium to Syneron Candela's 90-day volume-weighted average closing price through March 31, 2017, and a 33% premium to Syneron Candela's 90-day volume-weighted average closing price through February 10, 2017, the last trading day prior to media speculation of a transaction with funds advised by Apax. (NASDAQ: ELOS), a leading global non-surgical aesthetic device company, and Apax Partners, a leading global private equity advisory firm, today announced a definitive agreement under which an affiliate of funds advised by Apax Partners will acquire all of the outstanding shares of Syneron Candela for $11.00 per share in cash in a transaction valued at approximately $397 million.
and LONDON, Ap/PRNewswire/ - Syneron Medical Ltd.